SEC Form 4 · accession 0001144204-17-002333
OPIANT PHARMACEUTICALS, INC. · OPNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin Pollack
Officer — See Remarks · Director
Period of report
Jan 13, 2017
Accepted (ET)
Jan 17, 2017 · 9:54 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001385508
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 13, 2017 | P | 4,820 | $6.98 | A | 4,820 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $6.26 to $7.05, inclusive.
Remarks
Officer: Chief Financial Officer, Secretary and Treasurer